JP2022541332A5 - - Google Patents
Info
- Publication number
- JP2022541332A5 JP2022541332A5 JP2022505222A JP2022505222A JP2022541332A5 JP 2022541332 A5 JP2022541332 A5 JP 2022541332A5 JP 2022505222 A JP2022505222 A JP 2022505222A JP 2022505222 A JP2022505222 A JP 2022505222A JP 2022541332 A5 JP2022541332 A5 JP 2022541332A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204406A JP7506817B2 (ja) | 2019-07-26 | 2023-12-04 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| JP2025211395A JP2026064989A (ja) | 2019-07-26 | 2025-12-01 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878964P | 2019-07-26 | 2019-07-26 | |
| US62/878,964 | 2019-07-26 | ||
| US201962910650P | 2019-10-04 | 2019-10-04 | |
| US62/910,650 | 2019-10-04 | ||
| US202063030445P | 2020-05-27 | 2020-05-27 | |
| US63/030,445 | 2020-05-27 | ||
| PCT/IB2020/056972 WO2021019389A1 (en) | 2019-07-26 | 2020-07-23 | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204406A Division JP7506817B2 (ja) | 2019-07-26 | 2023-12-04 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| JP2025211395A Division JP2026064989A (ja) | 2019-07-26 | 2025-12-01 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541332A JP2022541332A (ja) | 2022-09-22 |
| JP2022541332A5 true JP2022541332A5 (enExample) | 2024-05-20 |
| JP7843226B2 JP7843226B2 (ja) | 2026-04-09 |
Family
ID=71895039
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505222A Active JP7843226B2 (ja) | 2019-07-26 | 2020-07-23 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| JP2023204406A Active JP7506817B2 (ja) | 2019-07-26 | 2023-12-04 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| JP2025211395A Pending JP2026064989A (ja) | 2019-07-26 | 2025-12-01 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204406A Active JP7506817B2 (ja) | 2019-07-26 | 2023-12-04 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| JP2025211395A Pending JP2026064989A (ja) | 2019-07-26 | 2025-12-01 | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12077585B2 (enExample) |
| EP (1) | EP4004057A1 (enExample) |
| JP (3) | JP7843226B2 (enExample) |
| KR (1) | KR20220040483A (enExample) |
| CN (1) | CN114375302B (enExample) |
| AU (1) | AU2020322222B2 (enExample) |
| BR (1) | BR112022001368A2 (enExample) |
| CA (1) | CA3147735A1 (enExample) |
| CL (3) | CL2022000142A1 (enExample) |
| CO (1) | CO2022001891A2 (enExample) |
| CR (1) | CR20220025A (enExample) |
| DO (1) | DOP2022000013A (enExample) |
| EC (1) | ECSP22015276A (enExample) |
| IL (1) | IL289897A (enExample) |
| MX (1) | MX2022001049A (enExample) |
| PE (1) | PE20220649A1 (enExample) |
| PH (1) | PH12022550195A1 (enExample) |
| TW (2) | TW202608931A (enExample) |
| UA (1) | UA129471C2 (enExample) |
| UY (1) | UY38803A (enExample) |
| WO (1) | WO2021019389A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220025A (es) | 2019-07-26 | 2022-05-04 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| PE20230389A1 (es) * | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas |
| JP7797469B2 (ja) * | 2020-07-17 | 2026-01-13 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｋｌｋ２抗体に対する抗イディオタイプ抗体 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| AU2022213825A1 (en) * | 2021-01-27 | 2023-09-14 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| CN116806159A (zh) * | 2021-01-27 | 2023-09-26 | 詹森生物科技公司 | 包含激肽释放酶相关肽酶2抗原结合结构域的免疫缀合物及其用途 |
| CA3211114A1 (en) * | 2021-02-16 | 2022-08-25 | Janssen Biotech, Inc. | Materials and methods for enhanced linker targeting |
| WO2022175255A2 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| CN117460747A (zh) * | 2021-03-24 | 2024-01-26 | 詹森生物科技公司 | 靶向CD79b、CD20和CD3的三特异性抗体 |
| CA3214594A1 (en) * | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Trispecific antibody targeting cd79b, cd20, and cd3 |
| AU2022246607A1 (en) * | 2021-03-31 | 2023-11-16 | Janssen Biotech, Inc. | Materials and methods for immune effector cells redirection |
| MX2023014069A (es) * | 2021-05-27 | 2024-03-15 | Janssen Biotech Inc | Composiciones y métodos para el tratamiento del cáncer de próstata. |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| WO2024089551A1 (en) * | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
| CN121925428A (zh) * | 2023-07-30 | 2026-04-24 | 詹森生物科技公司 | 结合突变钙网蛋白的分子及其用途 |
| WO2025085610A1 (en) | 2023-10-18 | 2025-04-24 | Janssen Biotech, Inc. | Combination treatment of prostate cancers with two bispecific antibodies |
| CN117187180B (zh) * | 2023-11-03 | 2024-01-26 | 四川大学 | 一种Th17细胞及其培养方法和应用及其诱导液 |
| WO2025226541A2 (en) | 2024-04-26 | 2025-10-30 | Janssen Biotech, Inc. | Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer |
| WO2025250739A1 (en) * | 2024-05-31 | 2025-12-04 | Janssen Biotech, Inc. | Chimeric antigen receptor with spacer domains derived from human igg |
| WO2026039420A1 (en) | 2024-08-13 | 2026-02-19 | Janssen Biotech, Inc. | Bispecific antibody targeting hk2 and cd3 for the treatment of prostate cancer |
| WO2026136030A1 (en) | 2024-12-18 | 2026-06-25 | Janssen Biotech, Inc. | Combination treatment of prostate cancer |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP3955636B2 (ja) | 1996-07-15 | 2007-08-08 | マヨ ファウンデーション フォーメディカル エデュケーション アンド リサーチ | Ｈｋ２ポリペプチドを検出するための方法 |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP1711828A2 (en) * | 2004-01-28 | 2006-10-18 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2) |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PL3248462T3 (pl) | 2010-03-31 | 2024-07-08 | Ablexis, Llc | Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| IN2014CN03887A (enExample) | 2011-10-27 | 2015-10-16 | Genmab As | |
| DK2771037T3 (en) | 2011-10-28 | 2016-11-14 | Fredax Ab | Therapeutics and uses thereof |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| BR112015000798A2 (pt) * | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| PT2970980T (pt) | 2013-03-15 | 2018-11-19 | Janssen Biotech Inc | Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes |
| WO2015075445A1 (en) * | 2013-11-19 | 2015-05-28 | Fredax Ab | Humanised anti kallikrein-2 antibody |
| GB2520353A (en) | 2013-11-19 | 2015-05-20 | Fredax Ab | Antibody polypeptides and uses thereof |
| CA2972800A1 (en) * | 2015-01-02 | 2016-07-07 | Dyax Corp. | Bispecific antibodies against plasma kallikrein and factor xii |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US20170096485A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
| US20180326102A1 (en) | 2015-11-18 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
| CN109843926B (zh) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | 针对cd3的双特异性抗体 |
| WO2018200582A1 (en) * | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| EP3684816B1 (en) | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| CR20220025A (es) | 2019-07-26 | 2022-05-04 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos |
| TW202118792A (zh) | 2019-07-26 | 2021-05-16 | 美商健生生物科技公司 | 抗hk2嵌合抗原受體(car) |
| AU2022213825A1 (en) | 2021-01-27 | 2023-09-14 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
-
2020
- 2020-07-23 CR CR20220025A patent/CR20220025A/es unknown
- 2020-07-23 UA UAA202200875A patent/UA129471C2/uk unknown
- 2020-07-23 BR BR112022001368A patent/BR112022001368A2/pt unknown
- 2020-07-23 PE PE2022000139A patent/PE20220649A1/es unknown
- 2020-07-23 CN CN202080054203.2A patent/CN114375302B/zh active Active
- 2020-07-23 KR KR1020227006607A patent/KR20220040483A/ko active Pending
- 2020-07-23 US US16/937,285 patent/US12077585B2/en active Active
- 2020-07-23 WO PCT/IB2020/056972 patent/WO2021019389A1/en not_active Ceased
- 2020-07-23 UY UY0001038803A patent/UY38803A/es active IP Right Grant
- 2020-07-23 EP EP20749947.6A patent/EP4004057A1/en active Pending
- 2020-07-23 JP JP2022505222A patent/JP7843226B2/ja active Active
- 2020-07-23 AU AU2020322222A patent/AU2020322222B2/en active Active
- 2020-07-23 TW TW114127271A patent/TW202608931A/zh unknown
- 2020-07-23 CA CA3147735A patent/CA3147735A1/en active Pending
- 2020-07-23 PH PH1/2022/550195A patent/PH12022550195A1/en unknown
- 2020-07-23 TW TW109124998A patent/TWI894157B/zh active
- 2020-07-23 MX MX2022001049A patent/MX2022001049A/es unknown
-
2022
- 2022-01-16 IL IL289897A patent/IL289897A/en unknown
- 2022-01-20 CL CL2022000142A patent/CL2022000142A1/es unknown
- 2022-01-20 DO DO2022000013A patent/DOP2022000013A/es unknown
- 2022-02-22 CO CONC2022/0001891A patent/CO2022001891A2/es unknown
- 2022-02-25 EC ECSENADI202215276A patent/ECSP22015276A/es unknown
-
2023
- 2023-02-17 CL CL2023000499A patent/CL2023000499A1/es unknown
- 2023-12-04 JP JP2023204406A patent/JP7506817B2/ja active Active
- 2023-12-27 US US18/397,711 patent/US20240124583A1/en active Pending
-
2024
- 2024-05-15 CL CL2024001462A patent/CL2024001462A1/es unknown
-
2025
- 2025-12-01 JP JP2025211395A patent/JP2026064989A/ja active Pending
- 2025-12-16 US US19/422,086 patent/US20260152559A1/en active Pending